Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11977371 | 0.88 | TSHR (0.55) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL30532401 | 0.88 | TSHR (0.55) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL11977396 | 0.87 | POLB (0.51) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL18706425 | 0.83 | TSHR (0.50) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL13243155 | 0.83 | TSHR (0.50) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL18706424 | 0.83 | TSHR (0.50) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL11977373 | 0.82 | POLB (0.49) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL13995964 | 0.81 | POLB (0.69) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL13995868 | 0.81 | POLB (0.69) | POLBMAPK1CA12CA2TSHR | |
| SCHEMBL170949 | 0.80 | POLB (0.66) | POLBMAPK1CA12CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120209007-A9 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-08-16 | — | — | US | disclosed |
| US-20110319629-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319629-A1 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | ABL1, TYR, CD59 | POLB 3975/4885MAPK1 1709/4885CA12 396/4885 |
| US-20120209007-A9 | TITANIUM COMPOUNDS AND PROCESS FOR CYANATION OF IMINES | ABL1, TYR, CD59 | POLB 3975/4885MAPK1 1709/4885CA12 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.